JP2009528345A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009528345A5 JP2009528345A5 JP2008557240A JP2008557240A JP2009528345A5 JP 2009528345 A5 JP2009528345 A5 JP 2009528345A5 JP 2008557240 A JP2008557240 A JP 2008557240A JP 2008557240 A JP2008557240 A JP 2008557240A JP 2009528345 A5 JP2009528345 A5 JP 2009528345A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- arylaliphatic
- pharmaceutical composition
- aliphatic
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 108010022429 Polycomb-Group Proteins Proteins 0.000 claims 4
- 102000012425 Polycomb-Group Proteins Human genes 0.000 claims 4
- 125000001931 aliphatic group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052710 silicon Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 230000006907 apoptotic process Effects 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 210000000130 stem cell Anatomy 0.000 claims 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims 2
- -1 1,3-Dioxo-1,3 - dihydro -2H- isoindol-2-yl Chemical group 0.000 claims 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 2
- 239000012650 DNA demethylating agent Substances 0.000 claims 2
- 229940045805 DNA demethylating agent Drugs 0.000 claims 2
- 229940126190 DNA methyltransferase inhibitor Drugs 0.000 claims 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000002723 alicyclic group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- GPTXWRGISTZRIO-UHFFFAOYSA-N chlorquinaldol Chemical compound ClC1=CC(Cl)=C(O)C2=NC(C)=CC=C21 GPTXWRGISTZRIO-UHFFFAOYSA-N 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 239000003968 dna methyltransferase inhibitor Substances 0.000 claims 2
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229930185603 trichostatin Natural products 0.000 claims 2
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- JWOGUUIOCYMBPV-GMFLJSBRSA-N (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-GMFLJSBRSA-N 0.000 claims 1
- QRPSQQUYPMFERG-LFYBBSHMSA-N (e)-5-[3-(benzenesulfonamido)phenyl]-n-hydroxypent-2-en-4-ynamide Chemical compound ONC(=O)\C=C\C#CC1=CC=CC(NS(=O)(=O)C=2C=CC=CC=2)=C1 QRPSQQUYPMFERG-LFYBBSHMSA-N 0.000 claims 1
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 claims 1
- GVHFMGARASYPBP-UHFFFAOYSA-N 3-[3-(dihydroxyamino)-3-oxoprop-1-enyl]benzoic acid Chemical compound ON(O)C(=O)C=CC1=CC=CC(C(O)=O)=C1 GVHFMGARASYPBP-UHFFFAOYSA-N 0.000 claims 1
- IDYKCXHJJGMAEV-RRKCRQDMSA-N 4-amino-5-fluoro-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 IDYKCXHJJGMAEV-RRKCRQDMSA-N 0.000 claims 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical group O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- JTDYUFSDZATMKU-UHFFFAOYSA-N 6-(1,3-dioxo-2-benzo[de]isoquinolinyl)-N-hydroxyhexanamide Chemical compound C1=CC(C(N(CCCCCC(=O)NO)C2=O)=O)=C3C2=CC=CC3=C1 JTDYUFSDZATMKU-UHFFFAOYSA-N 0.000 claims 1
- LJIRBXZDQGQUOO-KVTDHHQDSA-N 6-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,4-dihydro-1,3,5-triazin-2-one Chemical compound C1NC(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LJIRBXZDQGQUOO-KVTDHHQDSA-N 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical group CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
- 108010002156 Depsipeptides Proteins 0.000 claims 1
- 206010059866 Drug resistance Diseases 0.000 claims 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 1
- PTJGLFIIZFVFJV-UHFFFAOYSA-N N'-hydroxy-N-(3-pyridinyl)octanediamide Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CN=C1 PTJGLFIIZFVFJV-UHFFFAOYSA-N 0.000 claims 1
- JWOGUUIOCYMBPV-UHFFFAOYSA-N OT-Key 11219 Natural products N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-UHFFFAOYSA-N 0.000 claims 1
- 102000002272 Polycomb Repressive Complex 2 Human genes 0.000 claims 1
- 108010000597 Polycomb Repressive Complex 2 Proteins 0.000 claims 1
- 108700008625 Reporter Genes Proteins 0.000 claims 1
- 229930189037 Trapoxin Natural products 0.000 claims 1
- 108010082820 apicidin Proteins 0.000 claims 1
- 229930186608 apicidin Natural products 0.000 claims 1
- 229960002756 azacitidine Drugs 0.000 claims 1
- 230000034994 death Effects 0.000 claims 1
- 229960003603 decitabine Drugs 0.000 claims 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000001671 embryonic stem cell Anatomy 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 210000001173 gonocyte Anatomy 0.000 claims 1
- 229960002474 hydralazine Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- QOSWSNDWUATJBJ-UHFFFAOYSA-N n,n'-diphenyloctanediamide Chemical compound C=1C=CC=CC=1NC(=O)CCCCCCC(=O)NC1=CC=CC=C1 QOSWSNDWUATJBJ-UHFFFAOYSA-N 0.000 claims 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims 1
- 229960005184 panobinostat Drugs 0.000 claims 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229950009215 phenylbutanoic acid Drugs 0.000 claims 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 claims 1
- 229960000244 procainamide Drugs 0.000 claims 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 1
- 229960004919 procaine Drugs 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 claims 1
- 108010060597 trapoxin A Proteins 0.000 claims 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims 1
- 229960000604 valproic acid Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77853206P | 2006-03-02 | 2006-03-02 | |
| US60/778,532 | 2006-03-02 | ||
| PCT/SG2006/000350 WO2007100304A1 (en) | 2006-03-02 | 2006-11-15 | Methods for cancer therapy and stem cell modulation |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013015684A Division JP2013121974A (ja) | 2006-03-02 | 2013-01-30 | 癌治療と幹細胞調節のための方法 |
| JP2013213366A Division JP5902138B2 (ja) | 2006-03-02 | 2013-10-11 | 癌治療と幹細胞調節のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009528345A JP2009528345A (ja) | 2009-08-06 |
| JP2009528345A5 true JP2009528345A5 (enExample) | 2010-01-07 |
| JP5468782B2 JP5468782B2 (ja) | 2014-04-09 |
Family
ID=38459334
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008557240A Expired - Fee Related JP5468782B2 (ja) | 2006-03-02 | 2006-11-15 | 癌治療と幹細胞調節のための方法 |
| JP2013015684A Pending JP2013121974A (ja) | 2006-03-02 | 2013-01-30 | 癌治療と幹細胞調節のための方法 |
| JP2013213366A Expired - Fee Related JP5902138B2 (ja) | 2006-03-02 | 2013-10-11 | 癌治療と幹細胞調節のための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013015684A Pending JP2013121974A (ja) | 2006-03-02 | 2013-01-30 | 癌治療と幹細胞調節のための方法 |
| JP2013213366A Expired - Fee Related JP5902138B2 (ja) | 2006-03-02 | 2013-10-11 | 癌治療と幹細胞調節のための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8058258B2 (enExample) |
| EP (2) | EP1993553B1 (enExample) |
| JP (3) | JP5468782B2 (enExample) |
| AU (1) | AU2006339445A1 (enExample) |
| SG (1) | SG170041A1 (enExample) |
| TW (1) | TW200812590A (enExample) |
| WO (1) | WO2007100304A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG185942A1 (en) * | 2007-11-02 | 2012-12-28 | Agency Science Tech & Res | Methods and compounds for preventing and treating a tumour |
| US8629275B2 (en) | 2008-09-08 | 2014-01-14 | Merck Sharp & Dohme Corp. | AHCY hydrolase inhibitors for treatment of hyper homocysteinemia |
| EP2331543A4 (en) * | 2008-09-26 | 2013-06-19 | Agency Science Tech & Res | 3-deazaneplanocin DERIVATIVES |
| WO2010111712A2 (en) * | 2009-03-27 | 2010-09-30 | Cold Spring Harbor Laboratory | Identification of rnai targets and use of rnai for rational therapy of chemotherapy-resistant leukemia and other cancers |
| US8491927B2 (en) | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
| SG180031A1 (en) * | 2010-10-15 | 2012-05-30 | Agency Science Tech & Res | Combination treatment of cancer |
| WO2012082436A2 (en) * | 2010-12-03 | 2012-06-21 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
| RU2606514C2 (ru) | 2010-12-03 | 2017-01-10 | Эпизайм, Инк. | Замещенные пуриновые и 7-деазапуриновые соединения |
| WO2012075500A2 (en) | 2010-12-03 | 2012-06-07 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| EP2709612A4 (en) * | 2011-05-19 | 2015-07-01 | Glax L L C | COMPOSITIONS AND METHODS OF TREATMENT AND PREVENTION OF CANCER BY TARGETING AND INHIBITION OF CANCER STEM CELLS |
| WO2013036846A2 (en) * | 2011-09-09 | 2013-03-14 | Koronis Pharmaceuticals, Incorporated | N4 derivatives of deoxycytidine prodrugs |
| EP2869852A4 (en) * | 2012-07-09 | 2016-04-20 | Metheor Therapeutics Corp | Oligonucleotide inhibitors of DNA methyltransferases and their use in the treatment of diseases |
| WO2014026198A1 (en) | 2012-08-10 | 2014-02-13 | Epizyme, Inc. | Inhibitors of protein methyltransferase dot1l and methods of use thereof |
| EP2892536B1 (en) | 2012-09-06 | 2019-12-18 | Epizyme, Inc. | Method of treating leukemia |
| WO2014062978A1 (en) * | 2012-10-17 | 2014-04-24 | Cedars-Sinai Medical Center | Molecular signatures of ovarian cancer |
| US20160010059A1 (en) * | 2013-03-06 | 2016-01-14 | The Regents Of The University Of California | EXPANSION OF HEMATOPOIETIC PROGENITOR CELLS BY HISTONE METHYLTRANSFERASE G9a INHIBITION |
| US9175032B2 (en) | 2013-03-15 | 2015-11-03 | Epizyme, Inc. | Methods of synthesizing substituted purine compounds |
| WO2016022563A1 (en) | 2014-08-04 | 2016-02-11 | Auburn University | Enantiomers of the 1',6'-isomer of neplanocin a |
| US20160271149A1 (en) * | 2015-03-16 | 2016-09-22 | Epinova Therapeutics Corp. | Therapeutic compounds that suppress protein arginine methyltransferase activity for reducing tumor cell proliferation |
| WO2020055663A1 (en) * | 2018-09-11 | 2020-03-19 | The Texas A&M University System | L-oligonucleotide inhibitors of polycomb repressive complex 2 (prc2) |
| WO2020057107A1 (zh) * | 2018-09-17 | 2020-03-26 | 诺未科技（北京）有限公司 | 一种组合物及其用途 |
| WO2023249714A1 (en) * | 2022-06-24 | 2023-12-28 | Memorial Sloan-Kettering Cancer Center | Therapeutic compositions and methods for activating double stranded rna response in cancer patients via dnmt1 targeted therapy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US510260A (en) | 1893-12-05 | Electric-arc-lighting system | ||
| US4968690A (en) | 1986-05-27 | 1990-11-06 | United States Government As Represented By The Secretary Of The Dept. Of Health And Human Services | 3-deazaneplanocin, intermediates for it, and antiviral composition and method of treatment using it |
| US4975434A (en) | 1986-05-27 | 1990-12-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antiviral and anticancer cyclopentenyl cytosine |
| JPH04327587A (ja) | 1991-04-26 | 1992-11-17 | Asahi Chem Ind Co Ltd | ６’−ｃ−アルキル−３−デアザネプラノシンａ誘導体、その製造法およびその用途 |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US6090622A (en) | 1997-03-31 | 2000-07-18 | The Johns Hopkins School Of Medicine | Human embryonic pluripotent germ cells |
| DK1064027T3 (da) | 1998-03-27 | 2008-09-08 | Genentech Inc | APO-2 Ligand-anti-her-2-antistofsynergier |
| SE517975C2 (sv) | 2000-05-30 | 2002-08-13 | Power Ab C | Fackverkskonstruktion av balkar sammansatta till ett tredimensionellt ramverk samt användning av en sådan fackverkskonstruktion |
| US20050191618A1 (en) | 2001-05-18 | 2005-09-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA) |
| EP1536688B1 (en) | 2002-09-13 | 2011-12-28 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian megakaryocyte progenitor cell |
| AU2003295444A1 (en) | 2002-11-15 | 2004-06-15 | The Board Of Trustees Of The University Of Illinois | Methods for in vitro expansion of hematopoietic stem cells |
| US20050245559A1 (en) | 2004-01-23 | 2005-11-03 | Koul Hari K | Treatment and prevention of prostate cancer |
| US20050266093A1 (en) | 2004-04-27 | 2005-12-01 | Mohapatra Shyam S | Nanogene therapy for cell proliferation disorders |
| CA2574176A1 (en) | 2004-07-20 | 2006-02-09 | Schering Corporation | Induction of apoptosis in toll-like receptor expressing tumor cells |
-
2006
- 2006-11-15 US US12/281,470 patent/US8058258B2/en not_active Expired - Fee Related
- 2006-11-15 WO PCT/SG2006/000350 patent/WO2007100304A1/en not_active Ceased
- 2006-11-15 EP EP06813130.9A patent/EP1993553B1/en not_active Not-in-force
- 2006-11-15 EP EP12175675.3A patent/EP2522352B1/en not_active Not-in-force
- 2006-11-15 AU AU2006339445A patent/AU2006339445A1/en not_active Abandoned
- 2006-11-15 JP JP2008557240A patent/JP5468782B2/ja not_active Expired - Fee Related
- 2006-11-15 SG SG201101385-1A patent/SG170041A1/en unknown
-
2007
- 2007-02-27 TW TW096106615A patent/TW200812590A/zh unknown
-
2011
- 2011-09-26 US US13/245,709 patent/US8211869B2/en not_active Expired - Fee Related
-
2013
- 2013-01-30 JP JP2013015684A patent/JP2013121974A/ja active Pending
- 2013-10-11 JP JP2013213366A patent/JP5902138B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009528345A5 (enExample) | ||
| Kouraklis et al. | Histone deacetylase inhibitors and anticancer therapy | |
| AU2003219803B8 (en) | Method of treating TRX mediated diseases | |
| US9393222B2 (en) | Use of HDAC and/or DNMT inhibitors for treatment of ischemic injury | |
| ES2342378T3 (es) | Inhibidor de degradacion de matriz extracelular del cartilago artrodial. | |
| JP2009539862A5 (enExample) | ||
| ES2711086T3 (es) | Reactivación de la expresión génica del VIH-1 para tratar la infección persistente por VIH | |
| JP2009545310A5 (enExample) | ||
| WO2011113013A2 (en) | Methods and compositions for treating viral or virally-induced conditions | |
| MY160652A (en) | Pharmaceutical composition for oral administration | |
| JP2006290863A (ja) | 胃腸障害の治療 | |
| JP2017535521A5 (enExample) | ||
| JP2014532722A5 (enExample) | ||
| JP2019526559A5 (enExample) | ||
| Hanikoglu et al. | Natural product inhibitors of histone deacetylases as new anticancer agents | |
| JP2009510165A5 (enExample) | ||
| WO2012063005A3 (fr) | Composition pharmaceutique et forme galenique a base de dronedarone et son procede de preparation | |
| CN102441167B (zh) | 含有芹菜素及芹菜素类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用 | |
| ES2964286T3 (es) | Método de tratamiento de la Esteatohepatitis no alcohólica avanzada | |
| Kouraklis et al. | Histone deacetylase inhibitors as a potential therapeutic agent for human cancer treatment | |
| JP6100510B2 (ja) | 抗感冒剤 | |
| KR20110133716A (ko) | Ｔ 세포 특이적 ｈｄａｃ 억제제 운반 | |
| WO2008122425A3 (en) | Oral compositions containing tacrolimus in amorphous form | |
| HK40090847A (zh) | 用於治疗和预防器官损伤的组蛋白乙酰化调节剂 | |
| Xi et al. | In vivo chemogenetic RNA editing of macrophages by bioengineered viruses for sepsis treatment |